Research Day
Fecal Microbiota Transplantation For Recurrent Clostridiodes Difficile Infections
Document Type
Abstract
Date
2019
Abstract
BACKGROUND: Clostridiodes difficile infections are the most common healthcare-associated infection in the United States. Initial episodes are treated with oral vancomycin, however, 1 in 4 patients will suffer from recurrent Clostridiodes difficile infections. Rates of relapse following treatment of recurrent Clostridiodes difficile infections increase with each subsequent failure of treatment, and has lead investigators to find a more effective therapy. The treatment guidelines for Clostridiodes difficile infections have recently been updated, and included fecal microbiota transplantation as a treatment therapy for multiple recurrent Clostridiodes difficile infections. Although fecal microbiota transplantation has been recently added to the treatment guidelines, its true effectiveness and potential for the treatment of Clostridium difficile infections remains unclear.
METHODS: A retrospective chart review of patients treated for recurrent Clostridiodes difficile infections with either fecal microbiota transplantation or oral vancomycin. The primary objective of this study was to determine if treatment recurrent Clostridium difficile infections with FMT or oral vancomycin results in less recurrent Clostridium difficile infections over a 10-week follow up period after treatment.
RESULTS: A total of 60 patients were analyzed in this study. Recurrent Clostridiodes difficile infections occurred in 3 (10.1%) patients treated with fecal microbiota transplantation and in 16 (50%) patients treated with oral vancomycin (p < 0.01). This resulted in an in an odds ratio of 0.12 (95% [CI], 0.03 to 0.48).
CONCLUSION: In patients with recurrent Clostridiodes difficile infections, treatment with fecal microbiota transplantation resulted in significantly less treatment failures than patients treated with oral vancomycin.